News Archive http://egalet.investorroom.com/ Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO® ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain http://egalet.investorroom.com/2017-12-15-Egalet-Receives-FDA-Tentative-Approval-for-Expanded-Label-for-ARYMO-R-ER-morphine-sulfate-C-II-an-Extended-Release-Morphine-Product-Formulated-with-Abuse-Deterrent-Properties-for-Treatment-of-Chronic-Pain - Intranasal abuse-deterrent claim to be added to ARYMO ER prescribing information label - Fri, 15 Dec 2017 06:02:00 -0500 http://egalet.investorroom.com/2017-12-15-Egalet-Receives-FDA-Tentative-Approval-for-Expanded-Label-for-ARYMO-R-ER-morphine-sulfate-C-II-an-Extended-Release-Morphine-Product-Formulated-with-Abuse-Deterrent-Properties-for-Treatment-of-Chronic-Pain Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain http://egalet.investorroom.com/2017-11-28-Egalet-Announces-Positive-Top-Line-Results-from-Phase-3-Study-Evaluating-Efficacy-and-Safety-of-Egalet-002-in-Patients-with-Moderate-to-Severe-Chronic-Low-Back-Pain Tue, 28 Nov 2017 06:02:00 -0500 http://egalet.investorroom.com/2017-11-28-Egalet-Announces-Positive-Top-Line-Results-from-Phase-3-Study-Evaluating-Efficacy-and-Safety-of-Egalet-002-in-Patients-with-Moderate-to-Severe-Chronic-Low-Back-Pain Egalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian™ Technology http://egalet.investorroom.com/2017-11-20-Egalet-Received-a-Grant-from-InnoBooster-to-Develop-a-Novel-Application-of-Guardian-TM-Technology Mon, 20 Nov 2017 06:02:00 -0500 http://egalet.investorroom.com/2017-11-20-Egalet-Received-a-Grant-from-InnoBooster-to-Develop-a-Novel-Application-of-Guardian-TM-Technology Egalet Announces Positive Top-Line Results from Phase 3 Safety Study Evaluating Safety of Egalet-002 http://egalet.investorroom.com/2017-11-16-Egalet-Announces-Positive-Top-Line-Results-from-Phase-3-Safety-Study-Evaluating-Safety-of-Egalet-002 Thu, 16 Nov 2017 14:50:00 -0500 http://egalet.investorroom.com/2017-11-16-Egalet-Announces-Positive-Top-Line-Results-from-Phase-3-Safety-Study-Evaluating-Safety-of-Egalet-002 Egalet Announces Third Quarter 2017 Financial Results http://egalet.investorroom.com/2017-11-08-Egalet-Announces-Third-Quarter-2017-Financial-Results -- Company to host conference call today at 8:30 a.m. ET -- Wed, 08 Nov 2017 06:02:00 -0500 http://egalet.investorroom.com/2017-11-08-Egalet-Announces-Third-Quarter-2017-Financial-Results